- Predictors of poor treatment response in pediatric autoimmune hepatitis and autoimmune sclerosing cholangitis
Predictors of poor treatment response in pediatric autoimmune hepatitis and autoimmune sclerosing cholangitis
Modern Pediatrics. Ukraine. (2025).7(151): 46-56. doi: 10.15574/SP.2025.7(151).4656
Dyba M. B.1, Berezenko V. S.1.2, Zadorozhna T. D.1
1SI “Ukrainian Center for Maternity and Childhood of NAMS of Ukraine”, Kyiv
2Bogomolets National Medical University, Kyiv, Ukraine
For citation: Dyba MB, Berezenko VS, Zadorozhna TD. (2025). Predictors of poor treatment response in pediatric autoimmune hepatitis and autoimmune sclerosing cholangitis. Modern Pediatrics. Ukraine. 7(151): 46-56. doi: 10.15574/SP.2025.7(151).4656.
Article received: Sep 08, 2025. Accepted for publication: Nov 09, 2025.
Autoimmune hepatitis (AIH) and autoimmune sclerosing cholangitis (ASC) in children require long-term immunosuppressive therapy; however, complete biochemical response is not achieved within 12 months in a proportion of patients, which adversely affects prognosis.
Aim – to identify predictors of treatment non-response at 12 months in children with AIH and ASC in order to optimise monitoring and guide timely treatment adjustment.
Materials and methods. A retrospective analysis included 55 children with AIH/ASC treated in 2018-2024: responders with complete biochemical response (n=34) and non-responders (n=21). Baseline clinical and laboratory data and liver biopsy findings were assessed. Relative risk (RR), odds ratio (OR) and 95% confidence interval (CI) were calculated.
Results. Non-response was associated with ASC (RR=1.73; 95% CI: 1.07-2.82), anaemia (RR=2.78; 95% CI: 1.30-5.92), thrombocytopenia (RR=9.71; 95% CI: 1.26-75.16), splenomegaly (RR=1.71; 95% CI: 1.17-2.50) and inflammatory bowel disease (IBD) (RR=2.63; 95% CI: 1.32-5.26). Histological predictors included cholangitis activity ≥2 (RR=2.65; 95% CI: 1.58-4.44), ductopenia (p<0.01), biliary interface activity (RR=3.51; 95% CI: 1.58-7.81), and ductular epithelial expression of p16 (RR=1.95; 95% CI: 1.15-3.31) and p21 (RR=5.00; 95% CI: 1.62-15.39).
Conclusions. Individual clinical and laboratory indicators, comorbid IBD, and histological features of biliary injury and cellular senescence activation (p16/p21) were associated with treatment non-response at 12 months and may inform intensified monitoring and timely adjustment of therapy.
The study was conducted in accordance with the Declaration of Helsinki. The protocol was approved by the local ethics committee. Written informed consent was obtained from the children’s legal guardians.
The authors declare no conflict of interest.
Keywords: children, autoimmune hepatitis, autoimmune sclerosing cholangitis, biochemical response.
REFERENCES
1. Anderson CM, Welle CL, Ludwig DR, Anderson MA, Khot R, Itani M et al. (2025). Autoimmune Disorders of the Liver and Biliary Tract. Radio Graphics. 45: e240126. https://doi.org/10.1148/rg.240126; PMid:40111901
2. Bateman AC, Hübscher SG. (2010). Cytokeratin expression as an aid to diagnosis in medical liver biopsies. Histopathology. 56: 415-425. https://doi.org/10.1111/j.1365-2559.2009.03391.x; PMid:20459548
3. Beretta-Piccoli BT, Vergani D, Mieli-Vergani G. (2018). Autoimmune sclerosing cholangitis: Evidence and open questions. J Autoimmun. 95: 15-25. https://doi.org/10.1016/j.jaut.2018.10.008; PMid:30366655
4. Bossen L, Gerussi A, Lygoura V, Mells GF, Carbone M, Invernizzi P. (2018). Support of precision medicine through risk-stratification in autoimmune liver diseases – histology, scoring systems, and non-invasive markers. Autoimmun Rev. 17: 854-865. https://doi.org/10.1016/j.autrev.2018.02.013; PMid:30005861
5. Burt AD, Ferrell LD, Hübscher SG. (2023). MacSween's Pathology of the Liver. Elsevier eBooks+. 8th Edition. Elsevier – OHCE.
6. Giorgio AD, D'Adda A, Marseglia A, Sonzogni A, Licini L et al. (2019). Biliary features in liver histology of children with autoimmune liver disease. Hepatol Int. 13: 510-518. https://doi.org/10.1007/s12072-019-09948-1; PMid:31069759
7. Giorgio AD, Vergani D, Mieli-Vergani G. (2022). Cutting edge issues in juvenile sclerosing cholangitis. Dig Liver Dis. 54: 417-427. https://doi.org/10.1016/j.dld.2021.06.028; PMid:34289942
8. Gregorio GV, Portmann B, Karani J, Harrison P, Donaldson PT et al. (2001). Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: A 16‐year prospective study. Hepatology. 33: 544-553. https://doi.org/10.1053/jhep.2001.22131; PMid:11230733
9. Harada K, Hsu M, Ikeda H, Zeniya M, Nakanuma Y. (2013). Application and Validation of a New Histologic Staging and Grading System for Primary Biliary Cirrhosis. J Clin Gastroenterol. 47: 174-181. https://doi.org/10.1097/MCG.0b013e31827234e4; PMid:23269312
10. Kounis I, Sebagh M, Evain M, Cailliez V, Roche B, De Martin E et al. (2023). Nodular regenerative hyperplasia is not a rare condition after liver transplantation: incidence, predictive factors, and impact on survival. Transplantation. 107(2): 410-419. https://doi.org/10.1097/TP.0000000000004303; PMid:36117256
11. Lohse AW, Sebode M, Bhathal PS, Clouston AD, Dienes HP, Jain D et al. (2022). Consensus recommendations for histological criteria of autoimmune hepatitis from the International AIH Pathology Group. Liver Int. 42: 1058-1069. https://doi.org/10.1111/liv.15217; PMid:35230735
12. Ludz C, Stirnimann G, Semela D, Mertens J, Kremer AE, Sinnreich MF et al. (2023). Epidemiology, clinical features and management of autoimmune hepatitis in Switzerland: a retrospective and prospective cohort study. Swiss Méd Wkly. 153: 40102. https://doi.org/10.57187/smw.2023.40102; PMid:37769636
13. Mack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ et al. (2020). Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology. 72: 671-722. https://doi.org/10.1002/hep.31065; PMid:31863477
14. Mieli‐Vergani G, Vergani D, Baumann U, Czubkowski P, Debray D, Dezsofi A et al. (2018). Diagnosis and Management of Pediatric Autoimmune Liver Disease. J Pediatr Gastroenterol Nutr. 66: 345-360. https://doi.org/10.1097/MPG.0000000000001801; PMid:29356770 PMCid:PMC12211198
15. Nagore N, Howe S, Boxer L, Scheuer PJ. (1989). Liver cell rosettes: structural differences in cholestasis and hepatitis. Liver. 9: 43-51. https://doi.org/10.1111/j.1600-0676.1989.tb00377.x; PMid:2466188
16. Nastasio S, Mosca A, Alterio T, Sciveres M, Maggiore G. (2023). Juvenile Autoimmune Hepatitis: Recent Advances in Diagnosis, Management and Long-Term Outcome. Diagnostics. 13: 2753. https://doi.org/10.3390/diagnostics13172753; PMid:37685291 PMCid:PMC10486972
17. Ozturk NB, Fiel MI, Schiano TD. (2022, Jul 19). Identification and clinical significance of nodular regenerative hyperplasia in primary sclerosing cholangitis. JGH Open. 6(9): 607-611. https://doi.org/10.1002/jgh3.12795; PMid:36091322 PMCid:PMC9446399
18. Pape S, Snijders RJALM, Gevers TJG, Chazouilleres O, Dalekos GN, Hirschfield GM et al. (2022). Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group. J Hepatol. 76: 841-849. https://doi.org/10.1016/j.jhep.2021.12.041; PMid:35066089
19. Portmann B, Zen Y. (2012). Inflammatory disease of the bile ducts – cholangiopathies: liver biopsy challenge and clinicopathological correlation. Histopathology. 60: 236-248. https://doi.org/10.1111/j.1365-2559.2011.03853.x; PMid:21668470
20. Ramonet M, Ramirez-Rodriguez N, Chávez FÁ, Arregui MC, Boldrini G, Osorio VB et al. (2022). Autoimmune hepatitis in pediatrics, a review by the Working Group of the Latin American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Arch Argent Pediatr. 120: 281-287. https://doi.org/10.5546/aap.2022.eng.281
21. Rastogi A, Nigam N, Gayatri R, Bihari C, Pamecha V. (2022). Biliary Epithelial Senescence in Cellular Rejection Following Live Donor Liver Transplantation. J Clin Exp Hepatol. 12: 1420-1427. https://doi.org/10.1016/j.jceh.2022.08.004; PMid:36340312 PMCid:PMC9630016
22. Ricciuto A, Kamath BM, Hirschfield GM, Trivedi PJ. (2023). Primary sclerosing cholangitis and overlap features of autoimmune hepatitis: A coming of age or an age-ist problem? J Hepatol. 79: 567-575. https://doi.org/10.1016/j.jhep.2023.02.030; PMid:36870613
23. Riffenburgh RH. (2020). Statistics in Medicine. 4th ed. Amsterdam: Academic Press, Elsevier: 738.
24. Stevens JP, Gupta NA. (2022). Recent Insights into Pediatric Primary Sclerosing Cholangitis. Clin Liver Dis. 26: 489-519. https://doi.org/10.1016/j.cld.2022.03.009; PMid:35868687
25. Volk ML, Reau N. (2021). Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: A Patient‐Friendly Summary of the 2019 AASLD Guidelines. Clin Liver Dis. 17: 85-89. https://doi.org/10.1002/cld.1080; PMid:33680442 PMCid:PMC7916435
26. Warner S, Rajanayagam J, Russell E, Lloyd C, Ferguson J et al. (2024). Biliary disease progression in childhood onset autoimmune liver disease: A 30-year follow-up into adulthood. JHEP Rep. 6: 100901. https://doi.org/10.1016/j.jhepr.2023.100901; PMid:38235169 PMCid:PMC10790098